Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24–35.
Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol. 1996;8:805–14.
Bonomo P, Merlotti A, Olmetto E, Bianchi A, Desideri I, Bacigalupo A, et al. What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2018;45:2122–38.
Chan SC, Cheng NM, Hsieh CH, Ng SH, Lin CY, Yen TC, et al. Multiparametric imaging using 18F-FDG PET/CT heterogeneity parameters and functional MRI techniques: prognostic significance in patients with primary advanced oropharyngeal or hypopharyngeal squamous cell carcinoma treated with chemoradiotherapy. Oncotarget. 2017;8: 62606–21.
Chen SW, Shen WC, Lin YC, Chen RY, Hsieh TC, Yen KY, et al. Correlation of pretreatment 18F-FDG PET tumor textural features with gene expression in pharyngeal cancer and implications for radiotherapy-based treatment outcomes. Eur J Nucl Med Mol Imaging, 2017;44:567–80.
Cheng NM, Fang YH, Chang JT, Huang CG, Tsan DL, Ng SH, et al. Textural features of pretreatment 18F-FDG PET/CT images: prognostic significance in patients with advanced T-stage oropharyngeal squamous cell carcinoma. J Nucl Med. 2013;54:1703–9.
Cheng NM, Fang YH, Lee LY, Chang JT, Tsan DL, Ng SH, et al. Zone-size non-uniformity of 18F-FDG PET regional textural features predicts survival in patients with oropharyngeal cancer. Eur J Nucl Med Mol Imaging. 2015;42:419–28.
Ewen ME. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev. 1994;13:45–66.
Fujima N, Hirata K, Shiga T, Li R, Yasuda K, Onimaru R, et al. Integrating quantitative morphological and intratumoural textural characteristics in FDG-PET for the prediction of prognosis in pharynx squamous cell carcinoma patients. Clin Radiol. 2018;73:1059.e1-8.
Hoshikawa H, Mori T, Maeda Y, Takahashi S, Ouchi Y, Yamamoto Y, et al: Influence of volumetric 4'-[methyl-11C]-thiothymidine PET/CT parameters for prediction of the clinical outcome of head and neck cancer patients. Ann Nucl Med 2017;31:63–70.
Huang YT, Kumar AR, Bhuta S. 18F-FDG PET/CT as a semiquantitative imaging marker in HPV-p16-positive oropharyngeal squamous cell cancers. Nucl Med Commun. 2015;36:16-20.
Joo YH, Yoo IeR, Cho KJ, Park JO, Nam IC, Kim MS. Preoperative 18F-FDG PET/CT and high-risk HPV in patients with oropharyngeal squamous cell carcinoma. Head Neck. 2014;36:323–7.
Kendi ATK, Magliocca K, Corey A, Nickleach DC, Galt J, Higgins K, et al. Do 18F-FDG PET/CT parameters in oropharyngeal and oral cavity squamous cell carcinomas indicate HPV status? Clin Nucl Med. 2015;40:e196–200.
Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J, Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol. 2010;94:30–5
Lydiatt WM, Patel SG, O’Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:122–37.
Nioche C, Orlhac F, Boughdad S, Reuzé S, Goya-Outi J, Robert C, et al. LIFEx: a freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Research. 2018;78:4786–9.
Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014; 55:414–22.
Orlhac F, Nioche C, Soussan M, Buvat I. Understanding Changes in Tumor Texture Indices in PET: A Comparison Between Visual Assessment and Index Values in Simulated and Patient Data. J Nucl Med. 2017; 58:387–92.
Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ, et al. Survival and human papillomavirus in oropharynx cancer in TAX 324: A subset analysis from an international phase III trial. Ann Oncol 2011; 22:1071–7.
Schillaci O, Urbano N. Personalized medicine: A new option for nuclear medicine and molecular imaging in the third millennium. Eur J Nucl Med Mol Imaging. 2017;44:563–6.
Schouten CS, Hakim S, Boellaard R, Bloemena E, Doornaert PA, Witte BI, et al. Interaction of quantitative 18F-FDG-PET-CT imaging parameters and human papillomavirus status in oropharyngeal squamous cell carcinoma. Head Neck. 2016;38:529–35.
Sherr CJ. D-type cyclins. Trends Biochem Sci. 1995;20:187–90.
Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 1995;9:1149–63.
Surov A, Meyer HJ, Höhn AK, Winter K, Sabri O, Purz S. Associations between [18F] FDG-PET and complex histopathological parameters including tumor cell count and expression of Ki 67, EGFR, VEGF, HIF-1α, and p53 in head and neck squamous cell carcinoma. Mol Imaging Biol. 2019;21:368–74.
Taberna M, Mena M, Pavón MA, Alemany L, Gillison ML, Mesía R. Human papillomavirus-related oropharyngeal cancer. Ann Oncol. 2017;28:2386–98.
Tahari AK, Alluri KC, Quon H, Koch W, Wahl RL, Subramaniam RM. FDG PET/CT imaging of oropharyngeal squamous cell carcinoma: characteristics of human papillomavirus-positive and -negative tumors. Clin Nucl Med. 2014;39:225–31.
Toyohara J, Kumata K, Fukushi K, Irie T, Suzuki K. Evaluation of 4'-[methyl-14C]thiothymidine for in vivo DNA synthesis imaging. J Nucl Med. 2006;47:1717–22.
Toyohara J, Okada M, Toramatsu C, Suzuki K, Irie T. Feasibility studies of 4'-[methyl-11C]thiothymidine as a tumor proliferation imaging agent in mice. Nucl Med Biol. 2008;35:67–74.
Toyohara J, Nariai T, Sakata M, Oda K, Ishii K, Kawabe T, et al. Whole-body distribution and brain tumor imaging with 11C-4DST: a pilot study. J Nucl Med. 2011;52:1322–8.Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, et al. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers. Ann Nucl Med. 2014;28:1020–6. Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, et al. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers. Ann Nucl Med. 2014;28:1020–6. Hoshikawa H, Yamamoto Y, Mori T, Kishino T, Fukumura T, Samukawa Y, et al. Predictive value of SUV-based parameters derived from pre-treatment (18)F-FLT PET/CT for short-term outcome with head and neck cancers. Ann Nucl Med. 2014;28:1020–6.
Tsuchida K, Sugai T, Uesugi N, Ishida K, Matsuura K, Sato I, et al. Expression of cell cycle-related proteins in oropharyngeal squamous cell carcinoma based on human papilloma virus status. Oncol Rep. 2017;38:908–16.
Wang HM, Cheng NM, Lee LY, Fang YH, Chang JT, Tsan DL, et al. Heterogeneity of 18F-FDG PET combined with expression of EGFR may improve the prognostic stratification of advanced oropharyngeal carcinoma. Int J Cancer. 2016;138:731–8.
Wang H, Wang B, Wei J, Meng L, Zhang Q, Qu C, et al. Molecular mechanisms underlying increased radiosensitivity in human papillomavirus-associated oropharyngeal squamous cell carcinoma. Int J Biol Sci. 2020;16:1035–43.
Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323–30.
Yokota T. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?. Int J Clin Oncol. 2014;19:211–9.